Continuing its commitment to clinical excellence, Medtronic, Inc. (NYSE: MDT), announced the start of an international study comparing the company's Endeavor® Resolute Zotarolimus-Eluting Coronary Stent with Abbott Laboratory's Xience® V Everolimus-Eluting Coronary Stent.
More...